


References

1. Abdalian, R, Dhar, P, Jhaveri, K, et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. *Hepatology* 2008; 47:949.
2. Abdo AA, Bain VG, Kichian K, Lee SS. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. *Hepatology* 2002;36(6):1393–1399
3. Abu-Elamgd, k, Demetris, J, Rakela, J, et al. Transplantation for primary biliary cirrhosis: Recurrence and outcome in 421 patients (abstract). *Hepatology* 1997; 26:176A.
4. Abdulkarim, AS, Petrovic, LM, Kim, WR, et al. Primary biliary cirrhosis: antinfectious disease caused by *Chlamydia pneumoniae*? *J Hepatol* 2004; 40:380.
5. Agarwal K, Czaja AJ, Jones DE, Donaldson PT. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. *Hepatology* 2000;31(1):49–53
6. AHRENS EH, Jr, PAYNE, MA, KUNKEL, HG, et al. Primary biliary cirrhosis. *Medicine (Baltimore)* 1950; 29:299.
7. Ala, A, Stanca, CM, Bu-Ghanim, M, et al. Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. *Hepatology* 2006; 43:525.




- 

- 


- 

27. Bergasa NV. Treatment of the Pruritus of Cholestasis. *Curr Treat Options Gastroenterol* 2004; 7:501.
28. Bergquist A, Glaumann H, Lindberg B, Broome U. Primary sclerosing cholangitis can present with acute liver failure: Report of two cases. *J Hepatol*. 2006;44:1005-1008
29. Bergquist A, Said K, Broome U. Changes over a 20-year period in the clinical presentation of primary sclerosing cholangitis in Sweden. *Scand J Gastroenterol* 2007; 42: 88-93
30. Bergquist, A, Ekbom, A, Olsson, R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. *J Hepatol* 2002; 36:321.
31. Bergquist, A, Lindberg, G, Saarinen, S, Broomé, U. Increased prevalence of primary sclerosing cholangitis among first-degree relatives. *J Hepatol* 2005; 42:252.
32. Bergquist, A, Montgomery, SM, Bahmanyar, S, et al. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. *Clin Gastroenterol Hepatol* 2008; 6:939.
33. Berstad AE, Aabakken L, Smith HJ, Aasen S, Boberg KM, Schrumpf E. Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis. *Clin Gastroenterol Hepatol* 2006;4:514-520.




- 

48. Brandt, DJ, MacCarty, RL, Charboneau, JW, et al. Gallbladder disease in patients with primary sclerosing cholangitis. *AJR Am J Roentgenol* 1988; 150:571.
49. Bridoux-Henno, L, Maggiore, G, Johanet, C, et al. Features and outcome of autoimmune hepatitis type 2 presenting with isolated positivity for anti-liver cytosol antibody. *Clin Gastroenterol Hepatol* 2004; 2:825.
50. Brooke BN, Dykes PW, Walker FC. A study of liver disorder in ulcerative colitis. *Postgrad Med J* 1961; 37: 245-251
51. Broome U, Olsson R, Loof L, Bodemar G, Hultcrantz R, Danielsson A, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. *Gut* 1996;38:610-615.
52. Bruggraber, SF, Leung, PS, Amano, K, et al. Autoreactivity to lipoate and a conjugated form of lipoate in primary biliary cirrhosis. *Gastroenterology* 2003; 125:1705.
53. Cameron, JL, Pitt, HA, Zinner, MJ, et al. Resection of hepatic duct bifurcation and transhepatic stenting for sclerosing cholangitis. *An Surg* 1988; 207:614.
54. Campbell MS, Lichtenstein GR, Rhim AD, Pazianas M, Faust T. Severity of liver disease does not predict osteopenia or low bonemineral density in primary sclerosing cholangitis. *Liver Int* 2005;25:311-316.




55. Candia L., J.Marquez, and L. R. Espinoza, "Autoimmune hepatitis and pregnancy: a rheumatologist's dilemma," *Seminars in Arthritis and Rheumatism*, vol. 35, no. 1, pp. 49–56, 2005.
56. Cangemi, JR, Wiesner, RH, Beaver, SJ, et al. Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. *Gastroenterology* 1989; 96:790.
57. Caramella, C, Avouac, J, Sogni, P, et al. Association between rheumatoid arthritis and primary biliary cirrhosis. *Joint Bone Spine* 2007; 74:279.
58. Carpenter HA, Czaja AJ. The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants. *ClinLiver Dis* 2002;6:685-705.
59. Cavazza, A, Caballería, L, Floreani, A, et al. Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. *Hepatology* 2009; 50:1162.
60. Chalasani N, Baluyut A, Ismail A, Zaman A, Sood G, Ghalib R, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. *HEPATOLOGY* 2000;31:7-11.





- 


67. Chari ST, Longnecker DS, Kloppel G. The diagnosis of autoimmune pancreatitis: a Western perspective. *Pancreas* 2009; 38:846–848. This study introduced the concept of type 1 and type 2 AIP.
68. Chari ST, Takahashi N, Levy MJ, et al. A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer. *Clin Gastroenterol Hepatol* 2009; 7:1097–1103. This study outlines an algorithm to differentiate AIP from pancreatic cancer based on the United States experience of AIP.
69. Chazouillères, O, Wendum, D, Serfaty, L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. *Hepatology* 1998; 28:296
70. Chen M, Shirai M, Liu Z, Arichi T, Takahashi H, Nishioka M. Efficient class II major histocompatibility complex presentation of endogenously synthesized hepatitis C virus core protein by Epstein-Barr virus-transformed B-lymphoblastoid cell lines to CD4(+) T cells. *J Virol* 1998; 72: 8301-8308
71. Christensen, E, Altman, DG, Neuberger, J, et al. Updating prognosis in primary biliary cirrhosis using a time-dependent Cox regression model. PBC1 and PBC2 trial groups. *Gastroenterology* 1993; 105:1865.




72. Chung H., T. Watanabe, M. Kudo, O. Maenishi, Y. Wakatsuki, and T. Chiba, "Identification and characterization of IgG4-associated autoimmune hepatitis," *Liver International*, vol. 30, no. 2, pp. 222–231, 2010.
73. Combes B, Emerson SS, Flye NL. The primary biliary cirrhosis (PBC) ursodiol (UDCA) plus methotrexate (MTX) or its placebo study (PUMPS) - a multicenter randomized trial. *Hepatology* 2003;38:210A-210A. abstract.
74. Combes, B, Emerson, SS, Flye, NL, et al. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. *Hepatology* 2005; 42:1184.
75. Combes, B, Markin, RS, Wheeler, DE, et al. The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis. *Hepatology* 1999; 30:602.
76. Cooper GS, Bynum ML, Somers EC: Recent insights in the epidemiology of autoimmune diseases: Improved prevalence estimates and understanding of clustering of diseases. *J Autoimmun* 2009, 33:197-207.
77. Corpechot C, Carrat F, Bahr A, Chretien Y, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. *Gastroenterology* 128: 297-303, 2005.







94. Czaja AJ. Safety issues in the management of autoimmune hepatitis. *Expert Opin Drug Safety* 2008;7:319-333.
95. Czaja AJ. Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients. *Semin Liver Dis* 2009;29(3):315–330
96. Czaja, AJ, Carpenter, HA, Manns, MP. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. *Gastroenterology* 1993; 105:1522
97. Czaja, AJ. The variant forms of autoimmune hepatitis. *Ann Intern Med* 1996; 125:588.
98. Czaja. The role of autoantibodies as diagnostic markers of autoimmune hepatitis. *Expert Rev Clin Immunol* 2006;2:33-48.
99. D'Souza R., P. Sinnott, M. J. Glynn, C. A. Sabin, and G.R. Foster, "An unusual form of autoimmune hepatitis in young Somalian men," *Liver International*, vol.25, no.2, pp.325–330, 2005.
100. DATTA DV, SHERLOCK S. Treatment of pruritus of obstructive jaundice with cholestyramine. *Br Med J* 1963; 1:216.
101. Davidson, A, Diamond, B. Autoimmune diseases. *N Engl J Med* 2001; 345:340.
102. Davies, YK, Cox, KM, Abdullah, BA, et al. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. *J Pediatr Gastroenterol Nutr* 2008; 47:61.



- 

- 


- 

- 


- 

- 

- 




159. Hindorf U, Jahed K, Bergquist A, et al. Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis. *J Hepatol* 2010; 52:106.
160. Hirano K, Tada M, Isayama H, et al. Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. *Gut*. 2007;56:1719Y1724.
161. Hirschfield GM, Al-Harhi N, Heathcote EJ: Review Current. Status of Therapy in Autoimmune Liver Disease. *Ther Adv Gastroenterol* 2009, 2:11-28.
162. Hirschfield, GM, Liu, X, Han, Y, et al. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. *Nat Genet* 2010; 42:655.
163. Hirschfield, GM, Liu, X, Xu, C, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. *N Engl J Med* 2009; 360:2544.
164. Hodgson, SF, Dickson, ER, Wahner, HW, et al. Bone loss and reduced osteoblast function in primary biliary cirrhosis. *Ann Intern Med* 1985; 103:855.
165. Hollingsworth, KG, Newton, JL, Taylor, R, et al. Pilot study of peripheral muscle function in primary biliary cirrhosis: potential implications for fatigue pathogenesis. *Clin Gastroenterol Hepatol* 2008; 6:1041.




- 


173. Ishikawa M, Okada J, Shibuya A, Kondo H. CRST syndrome (calcinosis cutis, Raynaud's phenomenon, sclerodactyly, and telangiectasia) associated with autoimmune hepatitis. *Intern Med* 1995; 34:6.
174. James, SP, Hoofnagle, JH, Strober, W, Jones, EA. NIH conference: Primary biliary cirrhosis: a model autoimmune disease. *Ann Intern Med* 1983; 99:500.
175. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. *N Engl J Med* 1995;333:958-963.
176. Johnson, PJ, McFarlane, IG. Meeting report: International Autoimmune Hepatitis Group. *Hepatology* 1993; 18:998.
177. Jones EA, Neuberger J, Bergasa NV. Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions. *QJM* 2002; 95:547.
178. Jones, DE, Metcalf, JV, Collier, JD, et al. Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. *Hepatology* 1997; 26:1138.
179. Jones, DE, Newton, JL. An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. *Aliment Pharmacol Ther* 2007; 25:471.
180. Jones, EA, Bergasa, NV. Why do cholestatic patients itch? *Gut* 1996; 38:644.




181. Jones, EA. Rationale for trials of long-term mycophenolate mofetil therapy for primary biliary cirrhosis. *Hepatology* 2002; 35:258.
182. Jorgensen, RA, Lindor, KD, Sartin, JS, et al. Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis. *J Clin Gastroenterol* 1995; 20:215.
183. Juran, BD, Atkinson, EJ, Schlicht, EM, et al. Primary biliary cirrhosis is associated with a genetic variant in the 3' flanking region of the CTLA4 gene. *Gastroenterology* 2008; 135:1200.
184. Kajiwar M, Gotohda N, Konishi M, et al. Incidence of the focal type of autoimmune pancreatitis in chronic pancreatitis suspected to be pancreatic carcinoma: experience of a single tertiary cancer center. *Scand J Gastroenterol* 2008; 43:110–116.
185. Kamisawa T, Egawa N, Tsuruta K, Okamoto A, Funata N. Primary sclerosing cholangitis may be overestimated in Japan. *J Gastroenterol* 2005; 40:318–319.
186. Kamisawa T, Okamoto A. Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease. *J Gastroenterol* 2006; 41:613–625.
187. Kamisawa T, Shimosegawa T, Okazaki K, et al. Standard steroid treatment for autoimmune pancreatitis. *Gut* 2009; 58:1504–1507. A large multicenter study which provides the strongest rationale and evidence for using corticosteroids in the treatment of AIP




188. Kamisawa T, Takuma K, Anjiki H, et al. Differentiation of autoimmune pancreatitis from pancreatic cancer by diffusion-weighted MRI. *Am J Gastroenterol* 2010 Mar 9[Epub ahead of print].
189. Kamisawa T, Yoshiike M, Egawa N, Nakajima H, Tsuruta K, Okamoto A. Treating patients with autoimmune pancreatitis: results from a long-term follow-up study. *Pancreatology* 2005;5:234-238.
190. Kamisawa, T, Egawa, N, Nakajima, H, et al. Clinical difficulties in the differentiation of autoimmune pancreatitis and pancreatic carcinoma. *Am J Gastroenterol* 2003; 98:2694.
191. Kamisawa, T, Egawa, N, Nakajima, H. Autoimmune pancreatitis is a systemic autoimmune disease. *Am J Gastroenterol* 2003; 98:2811.
192. Kamisawa, T, Tu, Y, Egawa, N, et al. Involvement of pancreatic and bile ducts in autoimmune pancreatitis. *World J Gastroenterol* 2006; 12:612.
193. Kamiyama T., T. Nouchi, S. Kojima, N. Murata, T. Ikeda, and C. Sato, "Autoimmune hepatitis triggered by administration of an herbal medicine," *American Journal of Gastroenterology*, vol. 92, no. 4, pp. 703–704, 1997.
194. Kanzler S, Gerken G, Löhr H, et al. Duration of immunosuppressive therapy in autoimmune hepatitis. *J Hepatol* 2001; 34:354.




195. Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. *Am J Gastroenterol* 2007; 102: 1042-1049
196. Kaplan MM, Cheng S, Price LL, Bonis PA. A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results. *Hepatology* 2004;39:915-923.
197. Kaplan MM, Gershwin ME: Primary biliary cirrhosis. *N Engl J Med* 2005, 353:1261-1273.
198. Kaplan MM, Schmid C, Provenzale D, et al. A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis. *Gastroenterology* 1999; 117:1173-1180.
199. Kaplan, AA, Halley, SE, Reardon, J, Sevigny, J. One year's experience using a rotating filter for therapeutic plasma exchange. *ASAIO Trans* 1989; 35:262.
200. Kaplan, MM, Bonis, PA. Modafinil for the treatment of fatigue in primary biliary cirrhosis. *Ann Intern Med* 2005; 143:546.
201. Kaplan, MM, Goldberg, MJ, Matloff, DS, et al. Effect of 25-hydroxyvitamin D3 on vitamin D metabolites in primary biliary cirrhosis. *Gastroenterology* 1981; 81:681.
202. Kaplan, MM. *Novosphingobium aromaticivorans*: a potential initiator of primary biliary cirrhosis. *Am J Gastroenterol* 2004; 99:2147.





- 


215. Kita, H, Naidenko, OV, Kronenberg, M, et al. Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. *Gastroenterology* 2002; 123:1031.
216. Klein R, Zanger UM, Berg T, Hopf U, Berg PA. Overlapping but distinct specificities of anti-liver-kidney microsome antibodies in autoimmune hepatitis type II and hepatitis C revealed by recombinant native CYP2D6 and novel peptide epitopes. *Clin Exp Immunol* 1999; 118: 290-297.
217. Kotlyar DS, Campbell MS, Reddy KR. Recurrence of diseases following orthotopic liver transplantation. *Am J Gastroenterol* 2006; 101:1370-1378.
218. Koulentaki, M, Ioannidou, D, Stefanidou, M, et al. Dermatological manifestations in primary biliary cirrhosis patients: a case control study. *Am J Gastroenterol* 2006; 101:541.
219. Krams, SM, Surh, CD, Coppel, RL, et al. Immunization of experimental animals with dihydrolipoamide acetyltransferase, as a purified recombinant polypeptide, generates mitochondrial antibodies but not primary biliary cirrhosis. *Hepatology* 1989; 9:411.
220. Krawitt, EL. Autoimmune hepatitis. *N Engl J Med* 2006; 354:54.
221. Kremer, AE, Martens, JJ, Kulik, W, et al. Increased serum autotaxin activity in cholestatic pruritus (abstract). *Hepatology* 2009; 50:376A.




-

- 

- 






- 

- 


271. Mella JG, Roschmann E, Maier KP, Volk BA: Association of primary biliary cirrhosis with the allele HLA-DPB1*0301 in a German population. *Hepatology* 1995, 21:398-402.
272. Mendes, FD, Jorgensen, R, Keach, J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. *Am J Gastroenterol* 2006; 101:2070.
273. Menon, KV, Angulo, P, Weston, S, et al. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. *J Hepatol* 2001; 35:316.
274. Mieli-Vergani G, Vergani D. De novo autoimmune hepatitis after liver transplantation. *J Hepatol* 2004;40(1):3–7
275. Migliaccio, C, Van de Water, J, Ansari, AA, et al. Heterogeneous response of antimitochondrial autoantibodies and bile duct apical staining monoclonal antibodies to pyruvate dehydrogenase complex E2: the molecule versus the mimic. *Hepatology* 2001; 33:792.
276. Miller, LC, Kaplan, MM. Serum interleukin-2 and tumor necrosis factor-alpha in primary biliary cirrhosis: decrease by colchicine and relationship to HLA-DR4. *Am J Gastroenterol* 1992; 87:465.
277. Mitchison HC, Palmer JM, Bassendine MF, Watson AJ, Record CO, James OF. A controlled trial of prednisolone treatment in primary biliary cirrhosis: three-year results. *J Hepatol* 1992;15:336-344.




- 

- 

292. Murphy GM, Ross A, Billing BH. Serum bile acids in primary biliary cirrhosis. *Gut* 1972; 13:201.
293. Nakamura K, M. Yoneda, S. Yokohama et al., "Efficacy of ursodeoxycholic acid in Japanese patients with type autoimmune hepatitis," *Journal of Gastroenterology and Hepatology*, vol. 13, no. 5, pp. 457–495, 1998.
294. Nakamura, M, Kondo, H, Mori, T, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. *Hepatology* 2007; 45:118.
295. Nakanuma, Y, Ohta, G. Nodular hyperplasia of the liver in primary biliary cirrhosis of early histological stages. *Am J Gastroenterol* 1987; 82:8.
296. Nakazawa, T, Ohara, H, Sano, H, et al. Cholangiography can discriminate sclerosing cholangitis with autoimmune pancreatitis from primary sclerosing cholangitis. *Gastrointest Endosc* 2004; 60:937.
297. Neuberger, J. Recurrent primary biliary cirrhosis. *Liver Transpl* 2003; 9:539.
298. Newton, JL, Davidson, A, Kerr, S, et al. Autonomic dysfunction in primary biliary cirrhosis correlates with fatigue severity. *Eur J Gastroenterol Hepatol* 2007; 19:125.




- 




- 


- 



339. Pratt DS, Flavin DP, Kaplan MM. The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. *Gastroenterology* 1996; 110:271.
340. Prince, MI, Chetwynd, A, Craig, WL, et al. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. *Gut* 2004; 53:865.
341. Prochazka, EJ, Terasaki, PI, Park, MS, et al. Association of primary sclerosing cholangitis with HLA-DRw52a. *N Engl J Med* 1990; 322:1842.
342. Propst, A, Propst, T, Lechleitner, M, et al. Hypercholesterolemia in primary biliary cirrhosis is no risk factor for atherosclerosis. *Dig Dis Sci* 1993; 38:379.
343. Prytz H, Keiding S, Björnsson E, et al. Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. *Hepatology* 2006; 44:1572.
344. Raina, A, Krasinskas, AM, Greer, JB, et al. Serum immunoglobulin G fraction 4 levels in pancreatic cancer: elevations not associated with autoimmune pancreatitis. *Arch Pathol Lab Med* 2008; 132:48.
345. Raina, A, Yadav, D, Krasinskas, AM, et al. Evaluation and management of autoimmune pancreatitis: experience at a large US center. *Am J Gastroenterol* 2009; 104:2295.



- 




- 


- 

- 

378. Sheth, SG, Bishop, MD, Shea, JC, et al. Association of primary sclerosing cholangitis (PSC) with the cystic fibrosis carrier state: Results of extensive genotypic and phenotypic analysis (abstract). *Gastroenterology* 2001; 120:A75.
379. Shetty, K, Rybicki, L, Brzezinski, A, et al. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. *Am J Gastroenterol* 1999; 94:1643.
380. Shi, J, Li, Z, Zeng, X, et al. Ursodeoxycholic acid in primary sclerosing cholangitis: meta-analysis of randomized controlled trials. *Hepatol Res* 2009; 39:865.
381. Shimoda S, Harada K, Niino H, Yoshizumi T, Soejima Y, Taketomi A, Maehara Y, Tsuneyama K, Nakamura M, Komori A, Migita K, Nakanuma Y, Ishibashi H, Selmi C, Gershwin ME: Biliary epithelial cells and primary biliary cirrhosis: The role of liver-infiltrating mononuclear cells. *Hepatology* 2008, 47:958-965
382. Shimoda, S, Van de Water, J, Ansari, A, et al. Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. *J Clin Invest* 1998; 102:1831.
383. Siegel, JL, Jorgensen, R, Angulo, P, Lindor, KD. Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis. *J Clin Gastroenterol* 2003; 37:183.



- 384. Slapak, GI, Saxena, R, Portmann, B, et al. Graft and systemic disease in long-term survivors of liver transplantation. *Hepatology* 1997; 25:195.
- 385. Soetikno, RM, Lin, OS, Heidenreich, PA, et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. *Gastrointest Endosc* 2002; 56:48.
- 386. Solano E, Khakhar A, Bloch M, et al. Liver transplantation for primary sclerosing cholangitis. *Transplant Proc.* 2003;35:2431-2434. Abstract
- 387. Sorokin, A, Brown, JL, Thompson, PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: A systematic review. *Atherosclerosis* 2007; 46:776.
- 388. Springer, J, Cauch-Dudek, K, O'Rourke, K, et al. Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis. *Am J Gastroenterol* 1999; 94:47.
- 389. Springer, JE, Cole, DE, Rubin, LA, et al. Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. *Gastroenterology* 2000; 118:145.




- 


- 

- 


- 




- mediated cytotoxicity and liver damage,” *Liver*,vol.7,no.6, pp. 307–315, 1987.
422. Verma S, Torbenson M, Thuluvath PJ. The impact of ethnicity on the natural history of autoimmune hepatitis. *Hepatology* 2007; 46:1828.
423. Vogel A, Heinrich E, Bahr MJ, Rifai K, Flemming P, Melter M, et al. Long-term outcome of liver transplantation for autoimmune hepatitis. *Clin Transplant* 2004;18:62-69
424. Vuoristo M, Farkkila M, Karvonen AL, et al. A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid. *Gastroenterology* 1995;108:1470-1478.
425. Wächter, B, Kyriatsoulis, A, Lohse, AW, et al. Characterization of liver cytokeratin as a major target antigen of anti-SLA antibodies. *J Hepatol* 1990; 11:232.
426. Wagner S, Gebel M, Meier P, et al. Endoscopic management of biliary tract strictures in primary sclerosing cholangitis. *Endoscopy*. 1996;28:546-551. Abstract
427. Wakabayashi T, Kawaura Y, Satomura Y, Watanabe H, Motoo Y, Sawabu N. Long-term prognosis of duct-narrowing chronic pancreatitis: strategy for steroid treatment. *Pancreas* 2005;30:31-39.



- 



441. Xu B, Broome U, Ericzon BG, Sumitran-Holgersson S. High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6. *Gut* 2002; 51: 120-127
442. Xu, L, Sakalian, M, Shen, Z, et al. Cloning the human betaretrovirus proviral genome from patients with primary biliary cirrhosis. *Hepatology* 2004; 39:151.
443. Yamazaki, K, Nakadate, I, Suzuki, K, et al. Eosinophilia in primary biliary cirrhosis. *Am J Gastroenterol* 1996; 91:516.
444. Yeoman AD, Al-Chalabi T, Karani JB, Quaglia A, Devlin J, Mieli-Vergani G, et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening. *HEPATOLOGY* 2008;48:863-870
445. Yoshida K, Toki F, Takeuchi T, et al. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. *Dig Dis Sci* 1995; 40:1561–1568.
446. Zamboni G, Luttges J, Capelli P, et al. Histopathological features of diagnostic and clinical relevance in autoimmune pancreatitis: a study on 53 resection specimens and 9 biopsy specimens. *Virchows Arch* 2004; 445:552–563.



447. Zein, CO, Beatty, K, Post, AB, et al. Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: A cross validated retrospective assessment. *Hepatology* 2006; 44:1564.
448. Zen Y, Fujii T, Harada K et al (2007) Th2 and regulatory immunereactions are increased in immunoglobulin G4-related sclerosingpancreatitis and cholangitis. *Hepatology* 45:1538–46
449. Zhang L, Notohara K, Levy MJ, et al. IgG4-positive plasma cell infiltration in the diagnosis of autoimmune pancreatitis. *Modpathol* 2007;20:23-28.
450. Züchner, D, Sternsdorf, T, Szostecki, C, et al. Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. *Hepatology* 1997; 26:1123.
451. Zauli, D, Ghetti, S, Grassi, A, et al. Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. *Hepatology* 1997; 25:1105.

